Rebranding generics as branded medicines – CJEU issues new guidance

Published

Dec 19 2022

Written By

Heidi Hurdle

Professional Support Lawyer
UK

I am the Professional Support Lawyer to Bird & Bird's market-leading Intellectual Property group in London.

The CJEU has provided welcome new guidance on when parallel importers can rebrand generic medicines with the original trade mark of the reference medicinal product.

Its ruling in Impexeco NV v Novartis AG and PI Pharma NV v Novartis AG (Joined cases C 253/20 and C 254/20) is one of series of landmark judgments concerning parallel imports of pharmaceuticals released by the CJEU last month. (See our article here for details of these other judgments which put parallel imports and new anti-tampering devices under the spotlight.)

Full article available on BioTalk. Read more here